6dxk - Revision history

OCA at 06:15, 11 October 2023

OCA — Wed, 11 Oct 2023 06:15:21 GMT

←Older revision		Revision as of 06:15, 11 October 2023
Line 3:		Line 3:
	<StructureSection load='6dxk' size='340' side='right'caption='[[6dxk]], [[Resolution\|resolution]] 3.05Å' scene=''>		<StructureSection load='6dxk' size='340' side='right'caption='[[6dxk]], [[Resolution\|resolution]] 3.05Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[6dxk]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6DXK OCA]. For a <b>guided tour on the structure components</b> use [~~http~~://proteopedia.org/fgij/fg.htm?mol=6DXK FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[6dxk]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6DXK OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6DXK FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=HJ4:(8S,11R,13S,14S,17S)-11-[4-(dimethylamino)phenyl]-17-(3,3-dimethylbut-1-yn-1-yl)-17-hydroxy-13-methyl-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one+(non-preferred+name)'>HJ4</scene></td></tr>	+	</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 3.05Å</td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[~~http~~://proteopedia.org/fgij/fg.htm?mol=6dxk FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6dxk OCA], [~~http~~://pdbe.org/6dxk PDBe], [~~http~~://www.rcsb.org/pdb/explore.do?structureId=6dxk RCSB], [~~http~~://www.ebi.ac.uk/pdbsum/6dxk PDBsum], [~~http~~://prosat.h-its.org/prosat/prosatexe?pdbcode=6dxk ProSAT]</span></td></tr>	+	<tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=HJ4:(8S,11R,13S,14S,17S)-11-[4-(dimethylamino)phenyl]-17-(3,3-dimethylbut-1-yn-1-yl)-17-hydroxy-13-methyl-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one+(non-preferred+name)'>HJ4</scene></td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6dxk FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6dxk OCA], [https://pdbe.org/6dxk PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6dxk RCSB], [https://www.ebi.ac.uk/pdbsum/6dxk PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6dxk ProSAT]</span></td></tr>
	</table>		</table>
	== Disease ==		== Disease ==
-	[~~[http~~://www.uniprot.org/uniprot/GCR_HUMAN GCR_HUMAN]] Defects in NR3C1 are a cause of glucocorticoid resistance (GCRES) [MIM:[~~http~~://omim.org/entry/138040 138040]]; also known as cortisol resistance. It is a hypertensive, hyperandrogenic disorder characterized by increased serum cortisol concentrations. Inheritance is autosomal dominant.<ref>PMID:12050230</ref> <ref>PMID:1704018</ref> <ref>PMID:7683692</ref> <ref>PMID:11589680</ref> <ref>PMID:11701741</ref>	+	[https://www.uniprot.org/uniprot/GCR_HUMAN GCR_HUMAN] Defects in NR3C1 are a cause of glucocorticoid resistance (GCRES) [MIM:[https://omim.org/entry/138040 138040]; also known as cortisol resistance. It is a hypertensive, hyperandrogenic disorder characterized by increased serum cortisol concentrations. Inheritance is autosomal dominant.<ref>PMID:12050230</ref> <ref>PMID:1704018</ref> <ref>PMID:7683692</ref> <ref>PMID:11589680</ref> <ref>PMID:11701741</ref>
	== Function ==		== Function ==
-	[~~[http~~://www.uniprot.org/uniprot/GCR_HUMAN GCR_HUMAN]] Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Could act as a coactivator for STAT5-dependent transcription upon growth hormone (GH) stimulation and could reveal an essential role of hepatic GR in the control of body growth. Involved in chromatin remodeling. Plays a significant role in transactivation.<ref>PMID:21664385</ref>	+	[https://www.uniprot.org/uniprot/GCR_HUMAN GCR_HUMAN] Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Could act as a coactivator for STAT5-dependent transcription upon growth hormone (GH) stimulation and could reveal an essential role of hepatic GR in the control of body growth. Involved in chromatin remodeling. Plays a significant role in transactivation.<ref>PMID:21664385</ref>
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">
	== Publication Abstract from PubMed ==		== Publication Abstract from PubMed ==
Line 27:		Line 28:
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
		+	[[Category: Homo sapiens]]
	[[Category: Large Structures]]		[[Category: Large Structures]]
-	[[Category: Chen, C]]	+	[[Category: Chen C]]
-	[[Category: Daqing, S]]	+	[[Category: Daqing S]]
-	[[Category: Du, X]]	+	[[Category: Du X]]
-	[[Category: Eksterowicz, J]]	+	[[Category: Eksterowicz J]]
-	[[Category: Fantin~~, V R~~]]	+	[[Category: Fantin VR]]
-	[[Category: Huang, E]]	+	[[Category: Huang E]]
-	[[Category: Huang, T]]	+	[[Category: Huang T]]
-	[[Category: Jackson, E]]	+	[[Category: Jackson E]]
-	[[Category: Jahchan, N]]	+	[[Category: Jahchan N]]
-	[[Category: Kawai, H]]	+	[[Category: Kawai H]]
-	[[Category: McGee~~, L R~~]]	+	[[Category: McGee LR]]
-	[[Category: Medina~~, J C~~]]	+	[[Category: Medina JC]]
-	[[Category: Rew, Y]]	+	[[Category: Rew Y]]
-	[[Category: Sutimantanapi, D]]	+	[[Category: Sutimantanapi D]]
-	[[Category: Waszczuk, J]]	+	[[Category: Waszczuk J]]
-	[[Category: Yan, X]]	+	[[Category: Yan X]]
-	[[Category: Ye, Q]]	+	[[Category: Ye Q]]
-	[[Category: Zavorotinskaya, T]]	+	[[Category: Zavorotinskaya T]]
-	[[Category: Zhou, H]]	+	[[Category: Zhou H]]
-	[[Category: Zhu, L]]	+	[[Category: Zhu L]]
-	~~[[Category: Ligand complex]]~~	+
-	~~[[Category: Nuclear hormone receptor]]~~	+
-	~~[[Category: Signaling protein]]~~	+
-	~~[[Category: Transcription~~]]	+

OCA at 09:08, 11 November 2020

OCA — Wed, 11 Nov 2020 09:08:42 GMT

←Older revision		Revision as of 09:08, 11 November 2020
Line 1:		Line 1:

	==Glucocorticoid Receptor in complex with Compound 11==		==Glucocorticoid Receptor in complex with Compound 11==
-	<StructureSection load='6dxk' size='340' side='right' caption='[[6dxk]], [[Resolution\|resolution]] 3.05Å' scene=''>	+	<StructureSection load='6dxk' size='340' side='right'caption='[[6dxk]], [[Resolution\|resolution]] 3.05Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[6dxk]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6DXK OCA]. For a <b>guided tour on the structure components</b> use [http://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=6DXK FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[6dxk]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6DXK OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=6DXK FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=HJ4:(8S,11R,13S,14S,17S)-11-[4-(dimethylamino)phenyl]-17-(3,3-dimethylbut-1-yn-1-yl)-17-hydroxy-13-methyl-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one+(non-preferred+name)'>HJ4</scene></td></tr>	+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=HJ4:(8S,11R,13S,14S,17S)-11-[4-(dimethylamino)phenyl]-17-(3,3-dimethylbut-1-yn-1-yl)-17-hydroxy-13-methyl-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one+(non-preferred+name)'>HJ4</scene></td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=6dxk FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6dxk OCA], [http://pdbe.org/6dxk PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6dxk RCSB], [http://www.ebi.ac.uk/pdbsum/6dxk PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6dxk ProSAT]</span></td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=6dxk FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6dxk OCA], [http://pdbe.org/6dxk PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6dxk RCSB], [http://www.ebi.ac.uk/pdbsum/6dxk PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6dxk ProSAT]</span></td></tr>
	</table>		</table>
	== Disease ==		== Disease ==
Line 20:		Line 20:
	</div>		</div>
	<div class="pdbe-citations 6dxk" style="background-color:#fffaf0;"></div>		<div class="pdbe-citations 6dxk" style="background-color:#fffaf0;"></div>
		+
		+	==See Also==
		+	*[[Glucocorticoid receptor 3D structures\|Glucocorticoid receptor 3D structures]]
	== References ==		== References ==
	<references/>		<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
		+	[[Category: Large Structures]]
	[[Category: Chen, C]]		[[Category: Chen, C]]
	[[Category: Daqing, S]]		[[Category: Daqing, S]]

OCA at 07:48, 3 October 2018

OCA — Wed, 03 Oct 2018 07:48:59 GMT

←Older revision		Revision as of 07:48, 3 October 2018
Line 1:		Line 1:
-	'''Unreleased structure'''

-	~~The entry~~ 6dxk is ~~ON HOLD~~ ~~until Paper~~ Publication	+	==Glucocorticoid Receptor in complex with Compound 11==
		+	<StructureSection load='6dxk' size='340' side='right' caption='[[6dxk]], [[Resolution\|resolution]] 3.05Å' scene=''>
		+	== Structural highlights ==
		+	<table><tr><td colspan='2'>[[6dxk]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6DXK OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6DXK FirstGlance]. <br>
		+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=HJ4:(8S,11R,13S,14S,17S)-11-[4-(dimethylamino)phenyl]-17-(3,3-dimethylbut-1-yn-1-yl)-17-hydroxy-13-methyl-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one+(non-preferred+name)'>HJ4</scene></td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6dxk FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6dxk OCA], [http://pdbe.org/6dxk PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6dxk RCSB], [http://www.ebi.ac.uk/pdbsum/6dxk PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6dxk ProSAT]</span></td></tr>
		+	</table>
		+	== Disease ==
		+	[[http://www.uniprot.org/uniprot/GCR_HUMAN GCR_HUMAN]] Defects in NR3C1 are a cause of glucocorticoid resistance (GCRES) [MIM:[http://omim.org/entry/138040 138040]]; also known as cortisol resistance. It is a hypertensive, hyperandrogenic disorder characterized by increased serum cortisol concentrations. Inheritance is autosomal dominant.<ref>PMID:12050230</ref> <ref>PMID:1704018</ref> <ref>PMID:7683692</ref> <ref>PMID:11589680</ref> <ref>PMID:11701741</ref>
		+	== Function ==
		+	[[http://www.uniprot.org/uniprot/GCR_HUMAN GCR_HUMAN]] Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Could act as a coactivator for STAT5-dependent transcription upon growth hormone (GH) stimulation and could reveal an essential role of hepatic GR in the control of body growth. Involved in chromatin remodeling. Plays a significant role in transactivation.<ref>PMID:21664385</ref>
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	The glucocorticoid receptor (GR) has been linked to therapy resistance across a wide range of cancer types. Preclinical data suggest that antagonists of this nuclear receptor may enhance the activity of anticancer therapy. The first-generation GR antagonist mifepristone is currently undergoing clinical evaluation in various oncology settings. Structure-based modification of mifepristone led to the discovery of ORIC-101 (28), a highly potent steroidal GR antagonist with reduced androgen receptor (AR) agonistic activity amenable for dosing in androgen receptor positive tumors and with improved CYP2C8 and CYP2C9 inhibition profile to minimize drug-drug interaction potential. Unlike mifepristone, 28 could be codosed with chemotherapeutic agents readily metabolized by CYP2C8 such as paclitaxel. Furthermore, 28 demonstrated in vivo antitumor activity by enhancing response to chemotherapy in the GR(+) OVCAR5 ovarian cancer xenograft model. Clinical evaluation of safety and therapeutic potential of 28 is underway.

-	~~Authors~~:	+	Discovery of a Potent and Selective Steroidal Glucocorticoid Receptor Antagonist (ORIC-101).,Rew Y, Du X, Eksterowicz J, Zhou H, Jahchan N, Zhu L, Yan X, Kawai H, McGee LR, Medina JC, Huang T, Chen C, Zavorotinskaya T, Sutimantanapi D, Waszczuk J, Jackson E, Huang E, Ye Q, Fantin VR, Sun D J Med Chem. 2018 Sep 13;61(17):7767-7784. doi: 10.1021/acs.jmedchem.8b00743. Epub, 2018 Aug 23. PMID:30091920<ref>PMID:30091920</ref>

-	~~Description~~:	+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
-	[[Category: ~~Unreleased Structures~~]]	+	</div>
		+	<div class="pdbe-citations 6dxk" style="background-color:#fffaf0;"></div>
		+	== References ==
		+	<references/>
		+	__TOC__
		+	</StructureSection>
		+	[[Category: Chen, C]]
		+	[[Category: Daqing, S]]
		+	[[Category: Du, X]]
		+	[[Category: Eksterowicz, J]]
		+	[[Category: Fantin, V R]]
		+	[[Category: Huang, E]]
		+	[[Category: Huang, T]]
		+	[[Category: Jackson, E]]
		+	[[Category: Jahchan, N]]
		+	[[Category: Kawai, H]]
		+	[[Category: McGee, L R]]
		+	[[Category: Medina, J C]]
		+	[[Category: Rew, Y]]
		+	[[Category: Sutimantanapi, D]]
		+	[[Category: Waszczuk, J]]
		+	[[Category: Yan, X]]
		+	[[Category: Ye, Q]]
		+	[[Category: Zavorotinskaya, T]]
		+	[[Category: Zhou, H]]
		+	[[Category: Zhu, L]]
		+	[[Category: Ligand complex]]
		+	[[Category: Nuclear hormone receptor]]
		+	[[Category: Signaling protein]]
		+	[[Category: Transcription]]

OCA at 05:27, 18 July 2018

OCA — Wed, 18 Jul 2018 05:27:26 GMT

←Older revision		Revision as of 05:27, 18 July 2018
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

-	The entry 6dxk is ON HOLD	+	The entry 6dxk is ON HOLD until Paper Publication

	Authors:		Authors:

OCA: Protected "6dxk" [edit=sysop:move=sysop]

OCA — Wed, 11 Jul 2018 04:05:37 GMT

Protected "6dxk" [edit=sysop:move=sysop]

←Older revision

Revision as of 04:05, 11 July 2018

OCA: New page: '''Unreleased structure''' The entry 6dxk is ON HOLD Authors: Description: Category: Unreleased Structures

OCA — Wed, 11 Jul 2018 04:05:34 GMT

New page: '''Unreleased structure''' The entry 6dxk is ON HOLD Authors: Description: Category: Unreleased Structures

New page

'''Unreleased structure'''

The entry 6dxk is ON HOLD

Authors:

Description:
[[Category: Unreleased Structures]]